Recent Finacing
Recent Raise
Reunion Neuroscience is a clinical-stage biopharma developing RE104, a fast-acting, short-duration 4‑OH‑DiPT serotonergic prodrug targeting 5‑HT2A; Phase 1 showed ~3–4-hour psilocybin-like effects, entering Phase 2 for postpartum depression.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
